



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Avi Ashkenazi et al. Docket No: 39780-1216R1C1D4
Serial No: 10/785,220 Group Art Unit: 1644
Filed: February 24, 2004 Examiner: Haddad, Maher M.

Title: **COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASES CHARACTERIZED BY A-33 RELATED ANTIGENS**

Express Mail Label No.: EV 582 627 053 US

Mailing Date: March 30, 2005

STATEMENT UNDER 37 C.F.R. §§ 1.821(f) and (g)

MS: AMENDMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450


Dear Sir:

Submitted herewith is a copy of the substitute sequence listing in computer readable form for this application. Applicants' representative states that the content of the attached diskette copy in computer readable form of the sequence listing and the appended Sequence Listing paper copy, submitted in accordance with 37 C.F.R. 1.821 (c), (e) and (f) respectively, are identical.

Applicants' representative also state that the submission, filed in accordance with 37 C.F.R. §1.821(g), herein does not include new matter.


Respectfully submitted,

Date: March 30, 2005


Ginger R. Dreger, Esq.
Reg. No. 33,055

HELLER EHRMAN WHITE & McAULIFFE LLP

Customer No. 25213
275 Middlefield Road
Menlo Park, California 94025
Telephone: (650) 324-7000
Facsimile: (650) 324-0638



BEST AVAILABLE COPY

Application No.: 10/185,220

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

- ☒ 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
- ☐ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- ☐ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- ☐ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
- ☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- ☒ 7. Other: Fig 5 Contains a nucleic acid that is not present in sequence listing

Applicant Must Provide:

- ☒ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- ☒ An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- ☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

For PatentIn software help, call (703) 308-6856

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE